HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Diabetes & Endocrinology
RCT
GZR18 showed weight loss in Chinese adults with overweight or obesity in a phase 1b/2a trial
New Drug Cuts Weight by Nearly 20% in Just 35 Weeks
In this randomized, placebo-controlled phase 1b/2a trial, 60 Chinese adults with overweight or obesity received GZR18 or placebo.
This new treatment shows huge promise for helping people reach their weight goals without daily pills.
Apr 23, 2026
Cardiology
RCT
Memantine reduced PAC burden and new-onset AF in a Phase 2 randomized trial of 241 adults
Common Heart Flutters May Be Linked to Brain Drug
In this Phase 2 randomized, double-blind, placebo-controlled trial of 241 symptomatic adults with frequent PACs (≥1000/24 h), memantine show…
A new study shows a brain medication may calm frequent heart flutters and lower the risk of more serious heart rhythm problems.
Apr 22, 2026
Diabetes & Endocrinology
RCT
Secukinumab 300 mg subcutaneously failed to demonstrate overall response in adults with active Graves orbitopathy versus placebo
Secukinumab showed no benefit for active Graves orbitopathy patients
This randomized, double-blind, placebo-controlled trial evaluated secukinumab versus placebo in 28 adults with active, moderate-to-severe…
Secukinumab treatment for Graves orbitopathy showed no improvement in symptoms or eye measurements compared to placebo treatment.
Apr 22, 2026
Urology
RCT
In an RCT, dutasteride significantly reduced total International Prostate Symptom Score in men with lower urinary tract symptoms over 24 months
Dutasteride Helps Bladder Flow, But Nighttime Relief Takes Years
This randomized controlled trial enrolled 8122 men with lower urinary tract symptoms and compared dutasteride to placebo over a 24.0-month f…
This common prostate medication works well for flow, but full bladder comfort comes slowly and may not be noticeable.
Apr 21, 2026
Drug Pipeline
RCT
AI endoscopic score shows better agreement with ulcerative colitis remission than Mayo score in RCT
AI endoscopic scoring shows better agreement with ulcerative colitis symptoms in trial
This phase 3 RCT in 387 subjects with ulcerative colitis compared an AI endoscopic cumulative disease score (CDS) to the Mayo endoscopic sco…
An AI scoring system matched ulcerative colitis symptoms better than standard endoscopy, helping doctors align what they see with how patien…
Apr 19, 2026
Drug Pipeline
RCT
Efgartigimod shows homogeneous efficacy across sexes in AChR-Ab+ generalized myasthenia gravis
New Hope for All Myasthenia Gravis Patients
This post hoc, sex-specific subgroup analysis of the ADAPT Phase 3 RCT evaluated efgartigimod in 86 females and 43 males with AChR-Ab+ gener…
A new treatment for myasthenia gravis works equally well for women and men, offering the same relief from severe muscle weakness regardless …
Apr 18, 2026
Drug Pipeline
RCT
TTI-0102 Improves Fatigue Scores in MELAS Syndrome Patients During Randomized Phase 2 Trial
New Drug Reduces Fatigue in Rare Mitochondrial Disease
This randomized, single-blind, placebo-controlled Phase 2 trial enrolled 9 patients with MELAS syndrome caused by mtDNA m.3243A>G mutation.
This new medicine could finally give tired patients a sustainable boost in energy without the painful stomach issues that stop people from t…
medRxiv
Apr 18, 2026
Drug Pipeline
RCT
Phase 2 RCT of IV CN-105 in older adults undergoing noncardiac surgery shows fewer grade 2+ adverse events versus placebo
Could a simple IV drug help older adults avoid confusion after surgery?
This Phase 2 randomized clinical trial enrolled 203 older adults (60 years or older) scheduled for noncardiac or nonintracranial surgery.
A new IV drug given before surgery reduced confusion and side effects in older adults, though more testing is needed to confirm it truly pre…
Apr 17, 2026
Drug Pipeline
RCT
Deuruxolitinib 8 or 12 mg BID improved SALT20 response versus placebo in severe alopecia areata
Hair Regrowth Drug Shows Strong Results in Major Trial
This Phase 3 randomized, double-blind, placebo-controlled, multicenter trial enrolled 517 adults aged 18 to 65 years with severe chronic alo…
A new drug helped 38% of adults with severe hair loss regrow most of their hair in just six months during a major trial.
Apr 17, 2026
Drug Pipeline
RCT
Mazdutide monotherapy reduces HbA1c and promotes weight loss in Chinese adults with type 2 diabetes over 48 weeks
New Drug Lowers Sugar and Shrinks Weight in Diabetes
This phase 3 randomized controlled trial evaluated weekly subcutaneous mazdutide (4 mg or 6 mg) versus placebo in Chinese adults with type 2…
A new diabetes drug called mazdutide lowers blood sugar and shrinks weight in adults who struggle with diet and exercise alone.
Nat Med
Apr 16, 2026
Hematology
Phase II
Phase 2 trial tests single-dose IV iron isomaltoside in severe aortic stenosis with iron deficiency
Early study suggests iron treatment may help heart function in severe aortic stenosis patients
This Phase 2, double-blind, randomized, placebo-controlled trial tested a single intravenous dose of iron isomaltoside versus placebo in pat…
Treating iron deficiency may improve exercise capacity and reduce fatigue in people with severe aortic stenosis, according to early trial re…
CT.gov
Apr 16, 2026
Oncology
Phase III
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma
Could adding pembrolizumab help Chinese adults live longer with advanced biliary tract carcinoma?
This phase 3 randomized controlled trial enrolled 158 Chinese adults with advanced or unresectable biliary tract carcinoma.
A completed study in China compared adding pembrolizumab to chemotherapy for advanced bile duct cancer, tracking how long 158 adults survive…
CT.gov
Apr 16, 2026